The role of asunercept as a selective CD95L inhibitor in cutaneous melanoma: Rationale and results from an enhanced TiRP model
Asıl Yazarlar: | Krendyukov, A, Kneisel, N, Zhu, J, Merz, C, Richards, D, Gieffers, C, Van Den Eynde, B |
---|---|
Diğer Yazarlar: | Mitchell, T |
Materyal Türü: | Conference item |
Dil: | English |
Baskı/Yayın Bilgisi: |
Elsevier
2020
|
Benzer Materyaller
-
Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies
Yazar:: Krendyukov A, ve diğerleri
Baskı/Yayın Bilgisi: (2019-09-01) -
CD95L and Anti-Tumor Immune Response: Current Understanding and New Evidence
Yazar:: Richards DM, ve diğerleri
Baskı/Yayın Bilgisi: (2021-03-01) -
Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients
Yazar:: Nina Hanke, ve diğerleri
Baskı/Yayın Bilgisi: (2019-04-01) -
Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trialResearch in context
Yazar:: Maria Pilar Ruiz Seco, ve diğerleri
Baskı/Yayın Bilgisi: (2024-11-01) -
The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence
Yazar:: Charlotte Lemech, ve diğerleri
Baskı/Yayın Bilgisi: (2012-03-01)